S17 Ep28: In-House Molecular Testing in NSCLC Improves Turnaround Time, Tissue Stewardship, and Multidisciplinary Coordination: Featuring Anthony Chi, MD; Monica Peravali, MD; and Archana Jadhav, MD

About this episode

The episode discusses the benefits of in-house molecular testing for NSCLC with experts from the Mid-Atlantic Permanente Medical Group.

In today’s episode, we spoke with Anthony Chi, MD, a staff pathologist; Monica Peravali, MD, a medical oncologist; and Archana Jadhav, MD, a medical oncologist, all faculty at the Mid-Atlantic Permanente Medical Group in Maryland. In our exclusive interview, Drs Chi, Peravali, and Jadhav discussed the practical advantages and clinical implications of implementing in-house next-generation sequencing (NGS) testing for patients with non–small cell lung cancer (NSCLC). The conversation focused on how internal molecular testing platforms can improve turnaround times, optimize tissue stewardship, reduce costs, and enhance quality control across the diagnostic and treatment continuums. Chi explained that performing NGS internally eliminates delays associated with specimen transportation and external laboratory accessioning, significantly shortening turnaround times. He also highlighted Kaiser Permanente’s decision to implement a molecular platform distinct from those commonly used by outside vendors, allowing for reduced tissue input requirements and faster processing times. According to Chi, internal testing also gives pathology teams greater oversight of specimen use, enabling more…

People in this episode

Guests: Anthony Chi, MD, Monica Peravali, MD, Archana Jadhav, MD

Topics covered

• molecular testing
• non-small cell lung cancer
• next-generation sequencing
• tissue stewardship
• multidisciplinary coordination

Keywords

• molecular testing
• NGS
• turnaround time
• tissue stewardship
• biomarker testing
• pathology
• oncology

Mentioned in this episode

Organizations: Mid-Atlantic Permanente Medical Group, Kaiser Permanente

Books & works: non–small cell lung cancer (NSCLC)

Places: Maryland

More episodes of OncLive® On Air

• S17 Ep32: Previewing Key Myeloma Presentations to Watch at EHA 2026: With Joshua Richter, MD · June 10, 2026 · 10 min
• S17 Ep31: ASCO 2026 Plenary: RASolute 302 · June 8, 2026 · 11 min
• S17 Ep30: Tumor Board: Clinical Integration of Molecular Profiling in Glioma—Transforming the Use of Targeted Therapy · June 5, 2026 · 32 min
• S17 Ep29: Navigating Radiation, Systemic Therapy, and Multidisciplinary Care in Skin Cancer: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD, PhD; and Binh T. Ngo, MD · June 1, 2026 · 30 min
• S17 Ep27: Advances in Cervical Cancer: Prevention, Immunotherapy, and the Rise of Antibody-Drug Conjugates: With Ursula A. Matulonis, MD; and Meghan E. Shea, MD · May 27, 2026 · 16 min
• S17 Ep26: Emerging Targets, Second-Line Standards, and Molecular Subtyping Signal a New Era in SCLC Care: With Jacob Sands, MD · May 26, 2026 · 25 min